MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2026.117019

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2026

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Scafetta Roberta, Troiano Raffaella, Guarino Alessandra, Gullotta Carla, Fiore Cristina, Sisca Luisana, Speziale Elena, Travisani Arianna, Zannino Fernando, Miraglia Giovanni, Donato Marco, Foderaro Simone, Venuti Fabio, Vilardi Francesco Antonio, Ricozzi Valentina, Iuliani Michele, Simonetti Sonia, Cavaliere Silvia, Cortellini Alessio, La Cesa Annalisa, Di Mattia Andrea, Lombardo Michela, Angelone Martina, Botticelli Andrea, Scagnoli Simone, Pisegna Simona, Criscitiello Carmen, Pedersini Rebecca, Sposetti Caterina, Tiberi Elisa, D'Auria Giuliana, Vergati Matteo, Mazzotta Marco, Caputo Roberta, Verrazzo Annarita, Rossino Maria Grazia, Garrone Ornella, Domati Federica, Piombino Claudia, Gatti Federica, Filomeno Lorena, Arcuri Teresa, Puce Federica, Riva Federica, Palleschi Michela, Sirico Marianna, Piras Marta, Stucci Luigia Stefania, De Lisi Delia, Orsaria Paolo, Grasso Antonella, Ippolito Edy, Ramella Sara, Visani Luca, Livi Lorenzo, Gori Stefania, Rossi Luigi, Meattini Icro, Tagliaferri Barbara, Caffo Orazio, Portarena Ilaria, Irelli Azzurra, Cretella Elisabetta, Porta Camillo, Bianchini Giampaolo, Fabbri Maria Agnese, De Giorgi Ugo, Vici Patrizia, Toss Angela, Ruatta Fiorella, De Laurentiis Michelino, Villa Federica, Berardi Rossana, Minelli Mauro, Altomare Vittorio, Vernieri Claudio, Curigliano Giuseppe, Chirco Alessandra, D'Alessandro Sara, Vincenzi Bruno, Tonini Giuseppe, Santini Daniele, Pantano Francesco

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Bone-only HR+/HER2 - metastatic breast cancer generally has a favourable prognosis, but some patients develop visceral metastases. We aimed to quantify visceral conversion and identify reproducible baseline correlates during CDK4/6 inhibitor (CDK4/6i) therapy.

METHODS

This multicentre retrospective cohort included 692 patients treated with palbociclib, ribociclib, or abemaciclib plus endocrine therapy as first- or second-line treatment across 24 Italian centres. Visceral conversion was analysed in a competing-risks framework, with skeletal progression or death without prior visceral conversion as competing events. Eighteen baseline candidate predictors derived from a 35-variable dataset were evaluated using Fine-Gray modelling, ridge penalisation, bootstrap stability assessment, and cause-specific Cox sensitivity analyses.

RESULTS

Over a median follow-up of 31 months, 162 patients (23.4%) developed visceral conversion after a median of 17.0 months. Cumulative incidence was 8.8%, 17.5%, and 24.5% at 12, 24, and 36 months, respectively; median overall survival after visceral conversion was 18.0 months. Progesterone receptor (PR) expression was the most stable tumour-biological correlate, with complete sign concordance and a median absolute coefficient rank of 1 across 500 bootstrap resamples. In the mutually adjusted Fine-Gray model, higher PR expression was associated with lower visceral-conversion risk (sHR per 10-percentage-point increase, 0.929; 95% CI, 0.889-0.971; p = 0.0012), with consistent direction across complementary analyses. However, stand-alone PR prediction remained modest (24-month IPCW AUC, 0.585; Brier score, 0.142; IPA, 1.1%; O:E, 1.00), limiting individual-level clinical utility.

CONCLUSIONS

Broad baseline-variable profiling identified PR expression as the most reproducible tumour-biological correlate of visceral conversion, although its stand-alone predictive performance was modest.

Для цитирования: Scafetta Roberta, Troiano Raffaella, Guarino Alessandra, Gullotta Carla, Fiore Cristina, Sisca Luisana, Speziale Elena, Travisani Arianna, Zannino Fernando, Miraglia Giovanni, Donato Marco, Foderaro Simone, Venuti Fabio, Vilardi Francesco Antonio, Ricozzi Valentina, Iuliani Michele, Simonetti Sonia, Cavaliere Silvia, Cortellini Alessio, La Cesa Annalisa, Di Mattia Andrea, Lombardo Michela, Angelone Martina, Botticelli Andrea, Scagnoli Simone, Pisegna Simona, Criscitiello Carmen, Pedersini Rebecca, Sposetti Caterina, Tiberi Elisa, D'Auria Giuliana, Vergati Matteo, Mazzotta Marco, Caputo Roberta, Verrazzo Annarita, Rossino Maria Grazia, Garrone Ornella, Domati Federica, Piombino Claudia, Gatti Federica, Filomeno Lorena, Arcuri Teresa, Puce Federica, Riva Federica, Palleschi Michela, Sirico Marianna, Piras Marta, Stucci Luigia Stefania, De Lisi Delia, Orsaria Paolo, Grasso Antonella, Ippolito Edy, Ramella Sara, Visani Luca, Livi Lorenzo, Gori Stefania, Rossi Luigi, Meattini Icro, Tagliaferri Barbara, Caffo Orazio, Portarena Ilaria, Irelli Azzurra, Cretella Elisabetta, Porta Camillo, Bianchini Giampaolo, Fabbri Maria Agnese, De Giorgi Ugo, Vici Patrizia, Toss Angela, Ruatta Fiorella, De Laurentiis Michelino, Villa Federica, Berardi Rossana, Minelli Mauro, Altomare Vittorio, Vernieri Claudio, Curigliano Giuseppe, Chirco Alessandra, D'Alessandro Sara, Vincenzi Bruno, Tonini Giuseppe, Santini Daniele, Pantano Francesco. Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.. European journal of cancer (Oxford, England : 1990). 2026. DOI: 10.1016/j.ejca.2026.117019.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.